# Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma

> **NCT00017186** · PHASE2 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 69 (actual)

## Conditions studied

- Malignant Mesothelioma

## Interventions

- **DRUG:** epirubicin hydrochloride
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00017186
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-07
- **Primary completion:** 2004-08
- **Final completion:** 2008-05
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2016-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00017186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00017186, "Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00017186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*